HIV-1, HCV and alcohol in the CNS: Potential interactions and effects on neuroinflammation

Current HIV Research

Volumn 12, Issue 4, 2014, Pages 282-292

  Silverstein, Peter S ^a   Kumar, Santosh ^a   Kumar, Anil ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

AIDS; Alcohol; CNS; HCV; HIV 1; Neuroinflammation

Indexed keywords

ABACAVIR; ALCOHOL; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ATAZANAVIR; BOCEPREVIR; CHEMOKINE; CHOLINE; CREATINE; CYTOKINE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; ETRAVIRINE; INOSITOL; LOPINAVIR; MITOGEN ACTIVATED PROTEIN KINASE 3; NEVIRAPINE; TELAPREVIR; TRANSACTIVATOR PROTEIN; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DISEASE ASSOCIATION; DRUG ALCOHOL INTERACTION; DRUG METABOLISM; ENZYME ACTIVITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACELLULAR SIGNALING; LIVER TOXICITY; METABOLIC DISORDER; MIXED INFECTION; NERVOUS SYSTEM INFLAMMATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ALCOHOLISM; CENTRAL NERVOUS SYSTEM INFECTION; COMPLICATION; DRUG INTERACTION; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; IMMUNOLOGY; PATHOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ALCOHOLISM; ANTIVIRAL AGENTS; CENTRAL NERVOUS SYSTEM INFECTIONS; DRUG INTERACTIONS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; SIGNAL TRANSDUCTION;

EID: 84906262643     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140721122956     Document Type: Article

References (106)

1. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV Coinfection. Current HIV/AIDS reports. 2013; 10: 226-34.
2. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. Journal of virology. 2009; 83:7366-74.
3. Rees V, Saitz R, Horton NJ, Samet J. Association of alcohol consumption with HIV sex- and drug-risk behaviors among drug users. Journal of substance abuse treatment. 2001; 21:129-34.
4. Krupitsky EM, Horton NJ, Williams EC, Lioznov D, Kuznetsova M, Zvartau E, et al. Alcohol use and HIV risk behaviors among HIVinfected hospitalized patients in St. Petersburg, Russia. Drug and alcohol dependence. 2005; 79:251-6.
5. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. The American journal of gastroenterology. 1996; 91:498-505.
6. Lieber CS. Alcohol and hepatitis C. Alcohol research & health: the journal of the National Institute on Alcohol Abuse and Alcoholism. 2001; 25:245-54.
7. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. Journal of virology. 2002; 76:600-8.
8. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M, et al. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. Journal of virology. 2002; 76:10064-8.
9. Letendre S, Paulino AD, Rockenstein E, Adame A, Crews L, Cherner M, et al. Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. The Journal of infectious diseases. 2007; 196:361-70.
10. Wilkinson J, Radkowski M, Laskus T. Hepatitis C virus neuroinvasion: identification of infected cells. Journal of virology. 2009; 83:1312-9.
11. Murray J, Fishman SL, Ryan E, et al. Clinicopathologic correlates of hepatitis C virus in brain: a pilot study. Journal of neurovirology. 2008; 14:17-27.
12. Wilkinson J, Radkowski M, Eschbacher JM, Laskus T. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut. 2010; 59:1394-400.
13. Vivithanaporn P, Maingat F, Lin LT, N et al. Hepatitis C virus core protein induces neuroimmune activation and potentiates Human Immunodeficiency Virus-1 neurotoxicity. PloS one. 2010; 5:e12856.
14. Paulino AD, Ubhi K, Rockenstein E, Adame A, Crews L, Letendre S, et al. Neurotoxic effects of the HCV core protein are mediated by sustained activation of ERK via TLR2 signaling. Journal of neurovirology. 2011; 17:327-40.
15. Subramaniam S, Unsicker K. ERK and cell death: ERK1/2 in neuronal death. The FEBS journal. 2010; 277:22-9.
16. Genis P, Jett M, Bernton EW, et al. Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)- infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. The Journal of experimental medicine. 1992; 176:1703-18.
17. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nature reviews Immunology. 2005; 5:69-81.
18. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harbor perspectives in medicine. 2012; 2:a007120.
19. Mocchetti I, Bachis A, Avdoshina V. Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotoxicity research. 2012; 21:79-89.
20. Kaul M, Lipton SA. Mechanisms of neuroimmunity and neurodegeneration associated with HIV-1 infection and AIDS. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2006; 1:138-51.
21. D'Aversa TG, Yu KO, Berman JW. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. Journal of neurovirology. 2004; 10:86-97.
22. Lee EO, Kim SE, Park HK, Kang JL, Chong YH. Extracellular HIV- 1 Tat upregulates TNF-alpha dependent MCP-1/CCL2 production via activation of ERK1/2 pathway in rat hippocampal slice cultures: inhibition by resveratrol, a polyphenolic phytostilbene. Experimental neurology. 2011; 229:399-408.
23. Blanco AM, Valles SL, Pascual M, Guerri C. Involvement of TLR4/type I IL-1 receptor signaling in the induction of inflammatory mediators and cell death induced by ethanol in cultured astrocytes. Journal of immunology. 2005; 175:6893-9.
24. Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010; 30:8285-95.
25. Fernandez-Lizarbe S, Montesinos J, Guerri C. Ethanol induces TLR4/TLR2 association, triggering an inflammatory response in microglial cells. Journal of neurochemistry. 2013; 126:261-73.
26. Fletcher NF, Wilson GK, Murray J, Hu K, Lewis A, Reynolds GM, et al. Hepatitis C virus infects the endothelial cells of the blood-brain barrier. Gastroenterology. 2012; 142:634-43 e6.
27. Haorah J, Heilman D, Knipe B, Chrastil J, Leibhart J, Ghorpade A, et al. Ethanol-induced activation of myosin light chain kinase leads to dysfunction of tight junctions and blood-brain barrier compromise. Alcohol Clin Exp Res. 2005; 29:999-1009.
28. Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y. Alcoholinduced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. J Leukoc Biol. 2005; 78:1223-32.
29. Haorah J, Schall K, Ramirez SH, Persidsky Y. Activation of protein tyrosine kinases and matrix metalloproteinases causes blood-brain barrier injury: Novel mechanism for neurodegeneration associated with alcohol abuse. Glia. 2008; 56:78-88.
30. Pu H, Tian J, Andras IE, Hayashi K, et al. HIV-1 Tat protein-induced alterations of ZO-1 expression are mediated by redox-regulated ERK 1/2 activation. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2005; 25:1325-35.
31. Andras IE, Pu H, Tian J, et al. Signaling mechanisms of HIV-1 Tatinduced alterations of claudin-5 expression in brain endothelial cells. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2005; 25:1159-70.
32. Chang L, Munsaka SM, Kraft-Terry S, Ernst T. Magnetic resonance spectroscopy to assess neuroinflammation and neuropathic pain. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2013; 8:576-93.
33. Meyerhoff DJ, Durazzo TC, Ende G. Chronic alcohol consumption, abstinence and relapse: brain proton magnetic resonance spectroscopy studies in animals and humans. Current topics in behavioral neurosciences. 2013; 13:511-40.
34. Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor- Robinson SD. Evidence for a cerebral effect of the hepatitis C virus. Lancet. 2001; 358:38-9.
35. Weissenborn K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. Journal of hepatology. 2004; 41:845-51.
36. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology. 2005; 41:801-8.
37. Bokemeyer M, Ding XQ, Goldbecker A, Raab P, et al. Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy. Gut. 2011; 60:370-7.
38. Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. Journal of viral hepatitis. 2012; 19:e89-96.
39. Garvey LJ, Pavese N, Ramlackhansingh A, Thomson E, Allsop JM, Politis M, et al. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PloS one. 2012; 7:e38980.
40. Pattullo V, McAndrews MP, Damyanovich A, Heathcote EJ. Influence of hepatitis C virus on neurocognitive function in patients free from other risk factors: validation from therapeutic outcomes. Liver international: official journal of the International Association for the Study of the Liver. 2011; 31:1028-38.
41. Byrnes V, Miller A, Lowry D, et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. Journal of hepatology. 2012; 56:549-56.
42. Kraus MR, Schafer A, Teuber G, et al. Improvement of neurocognitive function in responders to an antiviral therapy for chronic hepatitis C. Hepatology. 2013; 58:497-504.
43. Chang L, Ernst T, Witt MD, Ames N, Gaiefsky M, Miller E. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naive HIV patients. NeuroImage. 2002; 17:1638-48.
44. Letendre SL, Zheng JC, Kaul M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. Journal of neurovirology. 2011; 17:63-9.
45. Gongvatana A, Harezlak J, Buchthal S, et al. Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. Journal of neurovirology. 2013; 19:209-18.
46. Ratai EM, Pilkenton SJ, Greco JB, et al. In vivo proton magnetic resonance spectroscopy reveals region specific metabolic responses to SIV infection in the macaque brain. BMC neuroscience. 2009; 10:63.
47. Ratai EM, Annamalai L, Burdo T, et al. Brain creatine elevation and N-Acetylaspartate reduction indicates neuronal dysfunction in the setting of enhanced glial energy metabolism in a macaque model of neuroAIDS. Magnetic resonance in medicine: official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. 2011; 66:625-34.
48. Schweinsburg BC, Taylor MJ, Videen JS, Alhassoon OM, Patterson TL, Grant I. Elevated myo-inositol in gray matter of recently detoxified but not long-term abstinent alcoholics: a preliminary MR spectroscopy study. Alcoholism, clinical and experimental research. 2000; 24:699-705.
49. Schweinsburg BC, Taylor MJ, Alhassoon OM, et al. Chemical pathology in brain white matter of recently detoxified alcoholics: a 1H magnetic resonance spectroscopy investigation of alcoholassociated frontal lobe injury. Alcoholism, clinical and experimental research. 2001; 25:924-34.
50. Bendszus M, Weijers HG, Wiesbeck G, et al. Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. AJNR American journal of neuroradiology. 2001; 22:1926-32.
51. Parks MH, Dawant BM, Riddle WR, et al. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. Alcoholism, clinical and experimental research. 2002; 26:1368-80.
52. Meyerhoff DJ, Blumenfeld R, Truran D, et al. Effects of heavy drinking, binge drinking, and family history of alcoholism on regional brain metabolites. Alcoholism, clinical and experimental research. 2004; 28:650-61.
53. Ende G, Welzel H, Walter S, et al. Monitoring the effects of chronic alcohol consumption and abstinence on brain metabolism: a longitudinal proton magnetic resonance spectroscopy study. Biological psychiatry. 2005; 58:974-80.
54. Ende G, Walter S, Welzel H, et al. Alcohol consumption significantly influences the MR signal of frontal choline-containing compounds. NeuroImage. 2006; 32:740-6.
55. Durazzo TC, Gazdzinski S, Yeh PH, Meyerhoff DJ. Combined neuroimaging, neurocognitive and psychiatric factors to predict alcohol consumption following treatment for alcohol dependence. Alcohol and alcoholism. 2008; 43:683-91.
56. Durazzo TC, Pathak V, Gazdzinski S, Mon A, Meyerhoff DJ. Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence. Journal of studies on alcohol and drugs. 2010; 71:278-89.
57. Senise JF, Castelo A, Martinez M. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy. AIDS reviews. 2011; 13:198-213.
58. Kress KD. HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy. American journal of health-system pharmacy: AJHP: official journal of the American Society of Health-System Pharmacists. 2004; 61 Suppl 3:S3-14; quiz S5-6.
59. Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology. 2006; 1:323-39.
60. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Expert opinion on drug metabolism & toxicology. 2007; 3:583-98.
61. Surgers L, Lacombe K. Hepatoxicity of new antiretrovirals: a systematic review. Clinics and research in hepatology and gastroenterology. 2013; 37:126-33.
62. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Current pharmaceutical design. 2005; 11:3697-710.
63. Bruno R, Sacchi P, Maiocchi L, Patruno S, Filice G. Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2006; 38:363-73.
64. Kontorinis N, Dieterich DT. Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Seminars in liver disease. 2003; 23:173-82.
65. Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Seminars in liver disease. 2003; 23:167-72.
66. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000; 14:2895-902.
67. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007; 21:1073-89.
68. Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial toxicity in HAART: an overview of in vitro evidence. Current pharmaceutical design. 2011; 17:2130-44.
69. Schweinsburg BC, Taylor MJ, Alhassoon OM, et al. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. Journal of neurovirology. 2005; 11:356-64.
70. Liner KJ, 2nd, Ro MJ, Robertson KR. HIV, antiretroviral therapies, and the brain. Current HIV/AIDS reports. 2010; 7:85-91.
71. Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? The Journal of antimicrobial chemotherapy. 2011; 66:1954-62.
72. Croteau D, Rossi SS, Best BM, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. The Journal of antimicrobial chemotherapy. 2013; 68:684-9.
73. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009; 23:1359-66.
74. Capparelli EV, Holland D, Okamoto C, et al. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS. 2005; 19:949-52.
75. Ferguson CS, Tyndale RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in pharmacological sciences. 2011; 32:708-14.
76. Hedlund E, Gustafsson JA, Warner M. Cytochrome P450 in the brain; a review. Current drug metabolism. 2001; 2:245-63.
77. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Current drug metabolism. 2007; 8:297-306.
78. Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drugmetabolizing enzymes. Drug metabolism and disposition: the biological fate of chemicals. 1992; 20:446-50.
79. Killer N, Hock M, Gehlhaus M, et al. Modulation of androgen and estrogen receptor expression by antiepileptic drugs and steroids in hippocampus of patients with temporal lobe epilepsy. Epilepsia. 2009; 50:1875-90.
80. Wang RW, Newton DJ, Scheri TD, Lu AY. Human cytochrome P450 3A4-catalyzed testosterone 6 beta-hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug metabolism and disposition: the biological fate of chemicals. 1997; 25:502-7.
81. Sulkowski MS. HCV therapy in HIV-infected patients. Liver international: official journal of the International Association for the Study of the Liver. 2013; 33 Suppl 1:63-7.
82. Rodriguez-Torres M. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient. Expert review of anti-infective therapy. 2012; 10:1117-28.
83. Rodriguez-Torres M, Slim J, Bhatti L, Sterling R, Sulkowski M, Hassanein T, et al. Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV clinical trials. 2012; 13:142-52.
84. Herbst DA, Reddy KR. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. Expert opinion on investigational drugs. 2013;.
85. Briani C, Chemello L, Zara G, Ermani M, Bernardinello E, Ruggero S, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology. 2006; 67:781-5.
86. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. The Journal of antimicrobial chemotherapy. 2010; 65:1079-85.
87. Rajani AK, Ravindra BK, Dkhar SA. Telaprevir: changing the standard of care of chronic hepatitis C. Journal of postgraduate medicine. 2013; 59:42-7.
88. Dumortier J, Guillaud O, Gagnieu MC, et al. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2013; 56:146-9.
89. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Annals of hepatology. 2012; 11:179-85.
90. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antiviral therapy. 2013;.
91. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012; 142:1324-34 e3.
92. Stickel F, Osterreicher CH. The role of genetic polymorphisms in alcoholic liver disease. Alcohol and alcoholism. 2006; 41:209-24.
93. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in alcoholinduced liver injury. Archives of toxicology. 2009; 83:519-48.
94. Wu D, Cederbaum AI. Oxidative stress mediated toxicity exerted by ethanol-inducible CYP2E1. Toxicology and applied pharmacology. 2005; 207:70-6.
95. Tanaka E, Terada M, Misawa S. Cytochrome P450 2E1: its clinical and toxicological role. Journal of clinical pharmacy and therapeutics. 2000; 25:165-75.
96. Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcoholism, clinical and experimental research. 1998; 22:2125-32.
97. Zhong Y, Dong G, Luo H, et al. Induction of brain CYP2E1 by chronic ethanol treatment and related oxidative stress in hippocampus, cerebellum, and brainstem. Toxicology. 2012; 302:275-84.
98. Haorah J, Knipe B, Leibhart J, Ghorpade A, Persidsky Y. Alcoholinduced oxidative stress in brain endothelial cells causes blood-brain barrier dysfunction. Journal of leukocyte biology. 2005; 78:1223-32.
99. Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of proteinaldehyde adducts in the liver of patients with alcoholic and nonalcoholic liver diseases. Journal of hepatology. 2000; 33:893-901.
100. McCance-Katz EF, Lum PJ, Beatty G, Gruber VA, Peters M, Rainey PM. Untreated HIV infection is associated with higher blood alcohol levels. Journal of acquired immune deficiency syndromes. 2012; 60:282-8.
101. Shibata Y, Takahashi H, Chiba M, Ishii Y. A novel approach to the prediction of drug-drug interactions in humans based on the serum incubation method. Drug metabolism and pharmacokinetics. 2008; 23:328-39.
102. Jin M, Arya P, Patel K, et al. Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages. Alcoholism, clinical and experimental research. 2011; 35:132-9.
103. Kumar S, Kumar A. Differential effects of ethanol on spectral binding and inhibition of cytochrome P450 3A4 with eight protease inhibitors antiretroviral drugs. Alcoholism, clinical and experimental research. 2011; 35:2121-7.
104. Kumar S, Earla R, Jin M, Mitra AK, Kumar A. Effect of ethanol on spectral binding, inhibition, and activity of CYP3A4 with an antiretroviral drug nelfinavir. Biochemical and biophysical research communications. 2010; 402:163-7.
105. Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, Kumar A. Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes. Expert opinion on drug metabolism & toxicology. 2012; 8:1363-75.
106. Shiu C, Barbier E, Di Cello F, Choi HJ, Stins M. HIV-1 gp120 as well as alcohol affect blood-brain barrier permeability and stress fiber formation: involvement of reactive oxygen species. Alcoholism, clinical and experimental research. 2007; 31:130-7.